FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891836054> ?p ?o ?g. }

• W2891836054 endingPage "1360" @default.
• W2891836054 startingPage "1352" @default.
• W2891836054 abstract "The relevance of granulocyte-macrophage colony-stimulating factor (GM-CSF) in the management of psoriasis has not been studied previously. GM-CSF is important in the initiation and maintenance of chronic inflammatory processes.To investigate the clinical use of GM-CSF neutralization by evaluating the efficacy and safety of namilumab (AMG203), a monoclonal antibody GM-CSF inhibitor, in patients with moderate-to-severe plaque psoriasis.A phase II, multicentre, randomized, double-blind, placebo-controlled, parallel-group, dose-finding, proof-of-concept study (NEPTUNE) was conducted. Four doses of namilumab (20, 50, 80 and 150 mg, via subcutaneous injection) were compared with placebo. Assessment of the primary end point - the proportion of patients achieving ≥ 75% reduction in Psoriasis Area and Severity Index (PASI 75 treatment response) - was performed at week 12. Exploratory investigation at the tissue level was conducted in a subset of the overall study population. The trial was registered with the number NCT02129777.In total, 122 patients were enrolled and 106 (86·9%) completed the double-blind treatment; 16 (13·1%) prematurely discontinued study medication. Serum concentration-time profiles were as expected for subcutaneous delivery of an IgG1 monoclonal antibody, and exposure increased proportionally with dose elevation. The number of patients showing PASI 75 treatment response at week 12 was low in all groups; no significant difference was recorded in this end point between placebo and any namilumab group. Similar outcomes were recorded for other clinical study end points. Moreover, no significant treatment-related changes from baseline were observed in laboratory investigations of cell types or subpopulations, or cytokines relevant to inflammatory pathways in psoriasis.GM-CSF blockade is not critical for suppression of key inflammatory pathways underlying psoriasis." @default.
• W2891836054 created "2018-09-27" @default.
• W2891836054 creator A5000030131 @default.
• W2891836054 creator A5006526834 @default.
• W2891836054 creator A5008286260 @default.
• W2891836054 creator A5032938103 @default.
• W2891836054 creator A5038255924 @default.
• W2891836054 creator A5064087231 @default.
• W2891836054 creator A5064706934 @default.
• W2891836054 creator A5077876525 @default.
• W2891836054 date "2019-06-01" @default.
• W2891836054 modified "2023-10-14" @default.
• W2891836054 title "Granulocyte–macrophage colony‐stimulating factor ( <scp>GM</scp> ‐ <scp>CSF</scp> ) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐ <scp>GM</scp> ‐ <scp>CSF</scp> monoclonal antibody" @default.
• W2891836054 cites W1491171312 @default.
• W2891836054 cites W1575886033 @default.
• W2891836054 cites W1617267715 @default.
• W2891836054 cites W1964106770 @default.
• W2891836054 cites W1965704185 @default.
• W2891836054 cites W1973354423 @default.
• W2891836054 cites W1981177225 @default.
• W2891836054 cites W1986828908 @default.
• W2891836054 cites W1988375787 @default.
• W2891836054 cites W2007905132 @default.
• W2891836054 cites W2019146519 @default.
• W2891836054 cites W2023408885 @default.
• W2891836054 cites W2024249616 @default.
• W2891836054 cites W2027605693 @default.
• W2891836054 cites W2029333156 @default.
• W2891836054 cites W2043897997 @default.
• W2891836054 cites W2044280032 @default.
• W2891836054 cites W2067327580 @default.
• W2891836054 cites W2073675282 @default.
• W2891836054 cites W2095395089 @default.
• W2891836054 cites W2096620879 @default.
• W2891836054 cites W2097315308 @default.
• W2891836054 cites W2099687194 @default.
• W2891836054 cites W2103001894 @default.
• W2891836054 cites W2106624302 @default.
• W2891836054 cites W2112006696 @default.
• W2891836054 cites W2113740916 @default.
• W2891836054 cites W2121126920 @default.
• W2891836054 cites W2121615890 @default.
• W2891836054 cites W2123946257 @default.
• W2891836054 cites W2127834887 @default.
• W2891836054 cites W2135741972 @default.
• W2891836054 cites W2139605495 @default.
• W2891836054 cites W2142285108 @default.
• W2891836054 cites W2154243215 @default.
• W2891836054 cites W2171889601 @default.
• W2891836054 cites W2184655932 @default.
• W2891836054 cites W2328527542 @default.
• W2891836054 cites W2592919377 @default.
• W2891836054 cites W823422456 @default.
• W2891836054 doi "https://doi.org/10.1111/bjd.17195" @default.
• W2891836054 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7379964" @default.
• W2891836054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30207587" @default.
• W2891836054 hasPublicationYear "2019" @default.
• W2891836054 type Work @default.
• W2891836054 sameAs 2891836054 @default.
• W2891836054 citedByCount "26" @default.
• W2891836054 countsByYear W28918360542018 @default.
• W2891836054 countsByYear W28918360542019 @default.
• W2891836054 countsByYear W28918360542020 @default.
• W2891836054 countsByYear W28918360542021 @default.
• W2891836054 countsByYear W28918360542022 @default.
• W2891836054 countsByYear W28918360542023 @default.
• W2891836054 crossrefType "journal-article" @default.
• W2891836054 hasAuthorship W2891836054A5000030131 @default.
• W2891836054 hasAuthorship W2891836054A5006526834 @default.
• W2891836054 hasAuthorship W2891836054A5008286260 @default.
• W2891836054 hasAuthorship W2891836054A5032938103 @default.
• W2891836054 hasAuthorship W2891836054A5038255924 @default.
• W2891836054 hasAuthorship W2891836054A5064087231 @default.
• W2891836054 hasAuthorship W2891836054A5064706934 @default.
• W2891836054 hasAuthorship W2891836054A5077876525 @default.
• W2891836054 hasBestOaLocation W28918360541 @default.
• W2891836054 hasConcept C126322002 @default.
• W2891836054 hasConcept C142724271 @default.
• W2891836054 hasConcept C168563851 @default.
• W2891836054 hasConcept C203014093 @default.
• W2891836054 hasConcept C203092338 @default.
• W2891836054 hasConcept C204787440 @default.
• W2891836054 hasConcept C27081682 @default.
• W2891836054 hasConcept C2776694085 @default.
• W2891836054 hasConcept C2777011040 @default.
• W2891836054 hasConcept C2777478134 @default.
• W2891836054 hasConcept C2777767877 @default.
• W2891836054 hasConcept C2778690821 @default.
• W2891836054 hasConcept C2780564577 @default.
• W2891836054 hasConcept C2908647359 @default.
• W2891836054 hasConcept C535046627 @default.
• W2891836054 hasConcept C71924100 @default.
• W2891836054 hasConcept C90924648 @default.
• W2891836054 hasConcept C99454951 @default.
• W2891836054 hasConceptScore W2891836054C126322002 @default.
• W2891836054 hasConceptScore W2891836054C142724271 @default.
• W2891836054 hasConceptScore W2891836054C168563851 @default.
• W2891836054 hasConceptScore W2891836054C203014093 @default.

• next